STA Wealth Management LLC bought a new position in shares of Idexx Laboratories (NASDAQ:IDXX) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,324 shares of the company’s stock, valued at approximately $636,000.

Several other hedge funds have also made changes to their positions in IDXX. Signaturefd LLC acquired a new position in Idexx Laboratories in the first quarter valued at about $105,000. Three Peaks Capital Management LLC acquired a new position in Idexx Laboratories in the first quarter valued at about $108,000. Optimum Investment Advisors acquired a new position in Idexx Laboratories in the first quarter valued at about $139,000. Financial Gravity Wealth Inc. acquired a new position in Idexx Laboratories in the first quarter valued at about $191,000. Finally, W.G. Shaheen & Associates DBA Whitney & Co acquired a new position in Idexx Laboratories in the first quarter valued at about $191,000. Institutional investors own 86.31% of the company’s stock.

Idexx Laboratories opened at $223.82 on Thursday, according to MarketBeat.com. The stock has a market cap of $19.20 billion, a PE ratio of 68.24, a price-to-earnings-growth ratio of 2.62 and a beta of 0.64. The company has a current ratio of 0.96, a quick ratio of 0.72 and a debt-to-equity ratio of -12.43. Idexx Laboratories has a one year low of $146.09 and a one year high of $224.50.

Idexx Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Friday, May 4th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.92 by $0.09. The business had revenue of $537.60 million during the quarter, compared to the consensus estimate of $525.14 million. Idexx Laboratories had a negative return on equity of 530.24% and a net margin of 13.87%. Idexx Laboratories’s quarterly revenue was up 16.4% on a year-over-year basis. During the same period last year, the company earned $0.77 earnings per share. research analysts anticipate that Idexx Laboratories will post 4.17 earnings per share for the current fiscal year.

Several equities analysts have weighed in on IDXX shares. Zacks Investment Research raised Idexx Laboratories from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a research note on Monday, May 21st. Stifel Nicolaus increased their target price on Idexx Laboratories from $215.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, May 7th. ValuEngine raised Idexx Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. BidaskClub lowered Idexx Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 9th. Finally, Credit Suisse Group increased their target price on Idexx Laboratories from $209.00 to $228.00 and gave the company an “outperform” rating in a research note on Friday, June 1st. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company. Idexx Laboratories currently has an average rating of “Buy” and an average price target of $218.43.

In other Idexx Laboratories news, Director William T. End sold 9,470 shares of the firm’s stock in a transaction that occurred on Thursday, May 10th. The stock was sold at an average price of $208.36, for a total value of $1,973,169.20. Following the completion of the transaction, the director now directly owns 31,786 shares in the company, valued at $6,622,930.96. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Jacqueline Studer sold 475 shares of the firm’s stock in a transaction that occurred on Wednesday, May 30th. The shares were sold at an average price of $209.98, for a total value of $99,740.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,571 shares of company stock valued at $2,405,215. 2.56% of the stock is owned by corporate insiders.

Idexx Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Idexx Laboratories (NASDAQ:IDXX).

Institutional Ownership by Quarter for Idexx Laboratories (NASDAQ:IDXX)

Receive News & Ratings for Idexx Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.